Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.1700
-0.0001-0.06%
Post-market: 0.17120.0012+0.71%16:36 EDT
Volume:10.03M
Turnover:1.75M
Market Cap:83.13M
PE:-0.26
High:0.1801
Open:0.1710
Low:0.1680
Close:0.1701
52wk High:3.87
52wk Low:0.1138
Shares:489.00M
Float Shares:306.00M
Volume Ratio:0.34
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6496
EPS(LYR):-0.7455
ROE:-783.37%
ROA:-62.39%
PB:-0.88
PE(LYR):-0.23

Loading ...

Gossamer Bio Plans September New Drug Application Submission for Potential Pulmonary Arterial Hypertension Treatment

MT Newswires Live
·
Jul 27

Gossamer Bio Shareholders Approved Convertible Note Exchange Proposals at Special Meeting

Reuters
·
Jul 27

Gossamer Bio - Plans Nda Submission for Seralutinib in Pah in September 2026

THOMSON REUTERS
·
Jul 27

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

THOMSON REUTERS
·
Jul 27

Gossamer Bio - Chiesi to Make One-Time $5 Mln Payment to Gossamer

THOMSON REUTERS
·
Jul 27

Gossamer Bio - Reacquires Worldwide Development and Commercial Rights to Seralutinib from Chiesi

THOMSON REUTERS
·
Jul 27

Gossamer Bio Inc: Co and Chiesi Agreed to Terminate Their Collaboration and License Agreement

THOMSON REUTERS
·
Jul 27

Gossamer Bio Shareholders Approve Charter Amendment Increasing Authorized Common Shares to 4 Billion

Reuters
·
Jul 15

Gossamer Bio announces determination of conversion rate for senior secured notes

TIPRANKS
·
Jul 01

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes Due 2030 and Exercise Price for Purchase Warrants

THOMSON REUTERS
·
Jul 01

Gossamer Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 26

Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright

TIPRANKS
·
Jun 26

Gossamer Bio Insiders Are Down US$45k But Regain Some Losses

Simply Wall St.
·
Jun 18

Gossamer Bio announces final tender results

TIPRANKS
·
Jun 17

Gossamer Bio says $18.95 million of 5% convertible notes due 2027 remain after exchange offer

Reuters
·
Jun 17

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation With Respect to Existing Convertible Notes

THOMSON REUTERS
·
Jun 17

Gossamer Bio - $181.1 Mln of Existing Convertible Notes Tendered as of June 2, 2026

THOMSON REUTERS
·
Jun 17

Gossamer Bio - Eliminates Most Restrictive Covenants and Events of Default on Existing Notes

THOMSON REUTERS
·
Jun 17

Harbour BioMed appoints Luisa Salter-Cid as scientific advisor

Reuters
·
Jun 11

Gossamer Bio accepts early tenders of USD 181.05 million 5% convertible notes in exchange offer

Reuters
·
Jun 05